Adlai Nortye Ltd's ROI from its fourth quarter of 2025 to the fourth quarter of 2023 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Adlai Nortye Ltd's ROI in the fourth quarter of 2025?
Due to the stockholders deficit and subsequent negative measured investments, it was not possible to calculate Adlai Nortye Ltd's return on investment (ROI) in its fourth quarter of 2025

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2023) IV. Quarter
Y / Y Investment Change TTM	-	-98.76 %	-	-	-
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	-7	-7	-7	-7	25
Return On Investment (TTM)	-	-	-	-	-160.88 %
ANL's Overall Ranking	#	#	#	#	#
Seq. Investment Change TTM	-	-95.5 %	-50.13 %	-33.39 %	-17.26 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-36	-105	-105	-105	-105

ANL Company Profile >> Back to ANL Roi Comparisons >> See Annual ANL Return On Investment

Return On Investment ANL's Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Investment Statistics
High	Average	Low
0 %	0 %	0 %

Financial Statements
Adlai Nortye Ltd's IV. Quarter Investments	$ -7 Millions	ANL's Balance sheet
Adlai Nortye Ltd's IV. Quarter Income	$ -36 Millions	Quarterly ANL's Income Statement
ANL's Income by Division		See ANL's Income by Division

ANL Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023
Total Investments in Millions	-7	25	76	0	0
Y / Y Investment Growth	-	-66.25 %	-	-	-
Net Income in Millions	-36	-52	-109	0	0
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-	-203.53 %	-144.64 %	-	-

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ANL's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ANL's Competitors
Subscribers only: Roi for Adlai Nortye Ltd's Suppliers
Subscribers only: Return On Investment for ANL's Customers

Other Ratios
ANL's Roa	ANL's Inventory Turnover Ratio	ANL's Growth Rates	ANL's Dividend Statistics
	ANL's Profitability Ratios	ANL's Asset Turnover Ratio	ANL's Dividend Growth
ANL's Roe	ANL's Valuation Ratios	ANL's Financial Strength Ratios	ANL's Dividend Payout Ratio

Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector	ROI
Capsovision Inc	865.95 %
Glucotrack Inc	372.04 %
Elutia Inc	358.27 %
Oncotelic Therapeutics Inc	252.91 %
Atara Biotherapeutics Inc	242.55 %
Traws Pharma inc	234.73 %
Scisparc Ltd	234.01 %
Petros Pharmaceuticals inc	233.39 %
Omada Health Inc	200.69 %
Interpace Biosciences Inc	198.59 %
Rigel Pharmaceuticals Inc	185.38 %
Icecure Medical Ltd	166.12 %
Silexion Therapeutics Corp	142.64 %
Heartflow Inc	142.09 %
Capforce Inc	140.91 %
Check Cap Ltd	120.45 %
Coherus Oncology inc	119.44 %
Kyntra Bio Inc	118.89 %
Lifemd Inc	105.75 %

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.